For 177 gram-negative isolates, the MICs for ciprofloxacin ranged from 0.02 ,ug/ml (Escherichia colt) to 0.31 ,ig/ml (Pseudomonas aeruginosa). In time-kill curves, ciprofloxacin at 8x the MIC almost completely killed 106 CFU of P. aeruginosa by 24 h. Ciprofloxacin at 4x the MIC allowed bacterial regrowth by 24 h, with development of partial resistance to ciprofloxacin.
Ciprofloxacin, a new quinoline carboxylic acid with wide antibacterial activity, has recently been the subject of much study (2) (3) (4) (5) (6) (7) . In this report, we evaluated the antibacterial activity of ciprofloxacin, its potential synergism with other drugs, and possible emergence of resistance to ciprofloxacin.
Organisms. The gram-negative bacteria tested were strains recently isolated from the blood or urine of patients at Montefiore Hospital, Pittsburgh, Pa.
MIC determinations. For agar dilution techniques, organisms were grown overnight in tryptic soy broth, then diluted 1:100 in Mueller-Hinton broth, grown for 2 to 5 h, and then adjusted to a 0. Time-kill curves. Killing curves with ciprofloxacin against two selected strains of Pseudomonas aeruginosa were performed. With an inoculum of 106 CFU, some killing was noted at 6 h, with regrowth at 24 h when concentrations of ciprofloxacin were 4x the MIC (Fig. 1A) . However, with a lower inoculum (104 CFU) and drug concentrations 2 x or 4 x the MIC, no regrowth was noted at 24 h (Fig. 1B) . With concentrations of ciprofloxacin 8x the MIC and with an inoculum of 106 CFU, killing was noted at 6 h, with no regrowth at 24 h (Fig. 1A) . Resistant colonies (MIC, 0,625 ,ug/ml) were only recovered at 24 h from mixtures containing high inocula (106 CFU) and lower concentrations of ciprofloxacin (4x the MIC); the MIC for the parent strain was 0.078 pg/ml. No ciprofloxacin-resistant colonies were recovered when high inocula (106 CFU) of bacteria were incubated with ciprofloxacin at 8 x the MIC or when lower inocula (104 CFU) were incubated with ciprofloxacin at 2 x or 4 x the MIC. This same phenomenon was also seen with both Klebsiella strains tested with ciprofloxacin.
Our data support preVious observations that ciprofloxacin, a carboxyquinoline derivative, has excellent activity against gram-negative organisms. Agar and broth dilution susceptibility studies gave similar results for most strains tested. Exceptions were noted for E. coli and Pseudomonas aeruginosa in which two-to fourfold differences in agar and broth sensitivities were noted.
ANTIMICROB. AGENTS CHEMOTHER. Prior experience with nalidixic acid, the prototype drug of this class, raised concern about development of bacterial resistance. Resistance to ciprofloxacin was produced when high inocula of certain gram-negative organisms were incubated with concentrations of ciprofloxacin at 4x the MIC. The induced resistance was not absolute and could be overcome by higher concentrations of ciprofloxacin. When bacteria were incubated with ciprofloxacin at concentrations of -8 x the MIC, no resistance developed after 24 h of incubation.
Others have made similar observations regarding the importance of antibiotic concentration in the development of resistance to ciprofloxacin. Eliopoulos et al. were able to produce significant resistance in Pseudomonas aeruginosa strains by initial exposure to ciprofloxacin at a concentration equal to 0.5 x the MIC and subsequent serial transfer to agar containing twofold incremental concentrations of the drug (3). Chin and Neu found a low frequency of resistance in Pseudomonas aeruginosa when the organism was exposed to concentrations of ciprofloxacin at 4x to 8x the MIC (2). These observations, and our data, suggest that if adequate multiples of the MIC for the infecting organism can be obtained in serum and tissue, resistance to ciprofloxacin may not be a frequent occurrence.
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